Subcutaneously injection of CD36-KO TAMs in a mouse model of lymphoma decreased tumor volume, impaired TAMs infiltration into tumor site, increased expression of M1-signature genes and decreased expression of M2-signature genes (34). This evidence concerns the gene CD36 and neoplasm.